Close Menu

expansion

The new Qlucore Diagnostics software builds on the recently updated Qlucore Omics Explorer platform, initially to help clinicians diagnose and treat leukemia.

Freshly minted as a "unicorn," the Utah healthcare data analytics powerhouse is building up a new life sciences division to aid biotech development and precision medicine.

The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.

The Shenzhen-based company offers personal genomics services in China that are similar to those provided by 23andMe, Ancestry, and Helix in the US.

The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.

Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.

The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.

LifeOmic, founded less than a year ago, expects omic data sets to become as clinically relevant as diagnostic medical imaging.

The La Jolla, California-based firm is moving beyond its US home market into other regions that promise growth for synthetic genomics providers.

The new division will enable BGI to expand partnerships with universities, companies, and health and agriculture-related organizations, among other things.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.